NCT06756035 - CT-95 in Advanced Cancers Associated With Mesothelin Expression | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2028

Conditions

Mesothelin-Expressing TumorsEpithelial Ovarian CancerMalignant Pleural Mesothelioma, AdvancedMalignant Peritoneal Mesothelioma, AdvancedPancreatic Adenocarcinoma Advanced or MetastaticLung Adenocarcinoma MetastaticCholangiocarcinoma AdvancedCholangiocarcinoma Non-resectableMesothelin-expressing Advanced CancersMesothelin-positive Advanced Malignant Solid TumorsColorectal Cancer

Interventions

DRUG

CT-95

Weekly IV dosing

Trial Locations (8)

19107

RECRUITING

Context Investigational Site, Philadelphia

37203

RECRUITING

Context Investigational Site, Nashville

49546

RECRUITING

Context Investigational Site, Grand Rapids

60637

RECRUITING

Context Investigational Site, Chicago

78229

RECRUITING

Context Investigational Site, San Antonio

RECRUITING

Context Investigational Site, San Antonio

80218

RECRUITING

Context Investigational Site, Denver

07601

RECRUITING

Context Investigational Site, Hackensack